

## RESEARCH ARTICLE

## Is Levodopa Response a Valid Indicator of Parkinson's Disease?

W.R. Wayne Martin, MD,<sup>1\*</sup> Michael Miles, MD,<sup>2</sup> Qiaonan Zhong, MD,<sup>3</sup> Johanna Hartlein, APRN,<sup>2</sup> Brad A. Racette, MD,<sup>2,4</sup> Scott A. Norris, MD,<sup>2,5</sup> Mwiza Ushe, MD,<sup>2</sup> Baijayanta Maiti, MD, PhD,<sup>2</sup> Susan Criswell, MD,<sup>2</sup> Albert A. Davis, MD, PhD,<sup>2</sup> Paul T. Kotzbauer, MD, PhD,<sup>2</sup> Nigel J. Cairns, PhD,<sup>6</sup> Richard J. Perrin, MD, PhD,<sup>2,7</sup> and Joel S. Perlmutter, MD<sup>2,5,8</sup>

<sup>1</sup>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada

<sup>2</sup>Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA

<sup>3</sup>Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

<sup>4</sup>Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Parktown, South Africa

<sup>5</sup>Department of Radiology, Washington University in St. Louis, St. Louis, Missouri, USA

<sup>6</sup>College of Medicine and Health, University of Exeter, Exeter, United Kingdom

<sup>7</sup>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri, USA

<sup>8</sup>Departments of Neuroscience, Physical Therapy and Occupational Therapy, Washington University in St. Louis, St. Louis, Missouri, USA

**ABSTRACT:** **Background:** The clinical diagnosis of Parkinson's disease (PD) requires the presence of parkinsonism and supportive criteria that include a clear and dramatic beneficial response to dopaminergic therapy. Our aim was to test the diagnostic criterion of dopaminergic response by evaluating its association with pathologically confirmed diagnoses in a large population of parkinsonian patients.

**Methods:** We reviewed clinical data maintained in an electronic medical record from all patients with autopsy data who had been seen in the Movement Disorders Center at Washington University, St. Louis, between 1996 and 2018. All patients with parkinsonism who underwent postmortem neuropathologic examination were included in this analysis.

**Results:** There were 257 unique parkinsonian patients with autopsy-based diagnoses who had received dopaminergic therapy. Marked or moderate response to dopaminergic therapy occurred in 91.2% (166/182) of those

with autopsy-confirmed PD, 52.0% (13/25) of those with autopsy-confirmed multiple systems atrophy, 44.4% (8/18) of those with autopsy-confirmed progressive supranuclear palsy, and 1 (1/8) with autopsy-confirmed corticobasal degeneration. Other diagnoses were responsible for the remaining 24 individuals, 9 of whom had a moderate response to dopaminergic therapy.

**Conclusion:** A substantial response to dopaminergic therapy is frequent but not universal in PD. An absent response does not exclude PD. In other neurodegenerative disorders associated with parkinsonism, a prominent response may also be evident, but this occurs less frequently than in PD. © 2020 International Parkinson and Movement Disorder Society

**Key Words:** Parkinson's disease; parkinsonism; levodopa; diagnostic specificity

\*Correspondence to: Dr. W.R. Wayne Martin, Department of Medicine (Neurology), University of Alberta, 963 Rice Road, Edmonton, AB, T6R1B1 Canada; Email: wmmartin@ualberta.ca

Relevant conflicts of interests/financial disclosures: None.

**Funding agencies:** This study was supported by grants from the National Institutes of Health (NS07532, NS097799, U10NS077384), the American Parkinson Disease Association (APDA), the Greater St. Louis Chapter of the APDA, the Jo Oertli Fund, the Barnes Jewish Hospital Foundation (Elliot Stein Family Fund and the Parkinson Disease Research Fund), and the Paula and Rodger Riney Fund.

**Received:** 31 July 2020; **Revised:** 7 November 2020; **Accepted:** 10 November 2020

Published online 30 November 2020 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28406

Parkinsonism is a clinical syndrome consisting of bradykinesia with rest tremor, rigidity, or both. The most common cause of parkinsonism, Parkinson's disease (PD), affects at least 1% of the population above age 60. Other neurodegenerative disorders, including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), are less common causes of parkinsonism. Although the differentiation of these conditions can present a diagnostic challenge to clinicians, their delineation is important for treatment and prognostication.

The clinical diagnosis of PD is based on its characteristic motor manifestations of parkinsonism and supportive criteria that include “clear and dramatic beneficial response to dopaminergic therapy.”<sup>1</sup> In a review of autopsy-confirmed patients, Hughes and colleagues provide evidence that not all PD cases have this degree of response to therapy.<sup>2</sup> The initial response to levodopa was reported as “nil to poor” in about 6% of patients. Furthermore, studies indicate that dopaminergic responsiveness may not be specific for a PD diagnosis.<sup>3-5</sup> Postmortem neuropathological evaluation remains the only definitive test to differentiate PD from other neurodegenerative disorders associated with parkinsonism.

Research on these syndromes is often limited by a lack of pathological confirmation of the clinically established diagnosis. We aim to address this limitation and test the current clinical diagnostic criterion of dopaminergic response by evaluating its association with pathologically confirmed diagnoses in a large population of parkinsonian patients treated in the Movement Disorders Center at Washington University School of Medicine in St. Louis.

## Patients and Methods

We reviewed clinical data maintained in an electronic medical record (EMR) from all patients treated in the Movement Disorders Center at Washington University, St. Louis, between 1996 and 2018 (n = 17,575). All patients at this center are routinely invited to participate in our brain donation program, regardless of clinical diagnosis. All those with parkinsonism (n = 8249) from this population who had subsequent autopsy confirmation of diagnosis underwent further analysis (n = 297). Each patient was examined by a subspecialty-trained movement disorders neurologist who recorded the clinical status in the EMR at each visit. The medication response was based on previously established clinically important differences in motor scores<sup>6</sup> and determined from the historical narrative supplemented by the Unified Parkinson's Disease Rating Scale (UPDRS) scores obtained in on- and off-medication states when available. The response was classified as marked if there was a >10-point change in the motor UPDRS associated with the use of dopaminergic medication or if the narrative indicated a marked symptomatic improvement or classified as moderate for a 5–10 point change in motor UPDRS or corresponding narrative. The response was considered nil in the absence of objective benefit, that is, improvement ≤3 points on the motor UPDRS (as suggested in the MDS clinical diagnostic criteria<sup>1</sup>) or corresponding narrative description. Dyskinesias and wearing off,

occurring at any time in the disease course, were recorded. Medication intake, expressed as levodopa equivalent dose (LED),<sup>7</sup> was recorded at the time of peak benefit early in the disease course estimated from the clinical record. Age of onset was defined as the patient's age at the first symptom of disease. Disease duration was defined as the interval between onset and death. The Washington University in St. Louis (WUSTL) Human Research Protection Office approved this study. All participants or their next of kin provided written informed consent.

Thorough neuropathologic examinations were performed at WUSTL as described in Franklin et al<sup>8</sup>; however, immunohistochemistry (IHC) for  $\alpha$ -synuclein using the LB509 monoclonal antibody was introduced in 1998 and was supplanted by IHC using phosphorylation-specific anti- $\alpha$ -synuclein antibodies in 2009 (167/257 [65%] autopsies were done using phosphorylation-specific antibodies).

Autopsy diagnoses were based on standard pathological criteria.<sup>9-14</sup> The diagnosis of PD was based on the presence of Lewy bodies within and the loss of pigmented neurons from the substantia nigra. Cortical  $\alpha$ -synuclein-positive inclusions consistent with Lewy bodies, although not required for the diagnosis of PD, were present in many of these patients. PSP patients had phospho-tau-immunoreactive astrocytes with “tufted” morphology neurofibrillary tangles and oligodendroglial inclusions (“coiled bodies”) in the typical distribution in cortex and subcortical nuclei. Those with MSA had  $\alpha$ -synuclein immunoreactive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. The diagnosis of CBD was based on the presence of several forms of tau-immunoreactive lesions, including astrocytic plaques, characteristic neuronal cytoplasmic inclusions (“corticobasal bodies”), coiled bodies, swollen achromatic “ballooned” neurons, and neuronal loss in cortex and basal ganglia.

Patient records with multiple pathologies were identified, looking specifically for PD, PSP, CBD, and MSA as well as a high likelihood of Alzheimer's disease (AD) based on the National Institute on Aging (NIA)-Reagan diagnostic criteria,<sup>15</sup> nonvascular amyloid plaque deposits not meeting these criteria for an AD diagnosis, TDP43 neuronal immunoreactivity,<sup>16</sup> and primary age-related tauopathy (PART).<sup>17</sup> Those with multiple pathologies were arbitrarily classified for further analysis by the non-PD movement disorder pathology.

Quantitative clinical data were compared with non-parametric tests, namely Kruskal-Wallis test followed by a post hoc pairwise multiple comparison procedure, or with a Student *t* test as appropriate. Categorical measures were compared using  $\chi^2$  test.

## Results

A total of 297 patient records, all with formal autopsy reports and a clinical diagnosis of parkinsonism, were reviewed. Of these, 257 patients had a trial of dopa-aminergic therapy and sufficiently detailed clinical records to be analyzed further. Pathological diagnoses of the excluded patients were PD (21), Alzheimer's disease (4), MSA (2), vascular disease (2), PSP (1), CBD (1), argyrophilic grain disease (1), neurodegeneration with brain iron accumulation (NBIA) (1), Huntington's disease (1), Creutzfeldt–Jakob disease (1), primary lateral sclerosis (1), and unexplained (4). The basic demographics and medication response are summarized in Table 1. Pathological diagnoses included PD in 182 (70.1%), MSA in 25 (9.7%), PSP in 18 (7%), and CBD in 8 (3.1%) participants. This distribution is

comparable to the general patient distribution in our center. A separate review of 3883 patients with parkinsonism showed a clinical diagnosis of MSA in 6%, PSP in 6%, and CBD in 1.7%, with the remainder being clinically diagnosed with PD (unpublished). The remaining 24 participants (9.3%), including 5 in whom the movement disorder remained unexplained after autopsy, had other pathological diagnoses, summarized in Table 2. These 24 participants were excluded from the statistical analyses.

Multiple pathologies were often present. In participants diagnosed with PD, AD was also present in 6, nonvascular amyloid deposition that did not meet criteria for AD in 127, TDP43 immunoreactivity in 17, and PART in 16. In participants with MSA, nonvascular amyloid was observed in 9, with no other co-pathologies evident. In participants with PSP, a

**TABLE 1.** Demographics and medication response

	Total group	Medication response		
		Marked	Moderate	Nil
<b>PD</b>				
Subjects (% total PD)	182	125 (68.7%)	41 (22.5%)	16 (8.8%)
Female (%)	29.1	30.4	31.7	12.5
Onset age (yr, mean $\pm$ SD)	60.8 $\pm$ 11.9	58.8 $\pm$ 12.5	61.7 $\pm$ 13.2	70.6 $\pm$ 9.1
Disease duration (yr, mean $\pm$ SD)	16.2 $\pm$ 7.7	17.8 $\pm$ 9.1	14.6 $\pm$ 8.5	10.4 $\pm$ 6.0
LED median/mean $\pm$ SD	650/766 $\pm$ 410	700/795 $\pm$ 438	600/639 $\pm$ 322	825/845 $\pm$ 308
LED range	150–2843	150–2843	190–1600	400–1500
Dyskinesia	121 (66.5%)	101 (80.8%)	20 (48.8%)	0
Wearing off	129 (70.9%)	106 (84.8%)	23 (56.1%)	0
<b>MSA</b>				
Subjects (% total MSA)	25	4 (16%)	9 (36%)	12 (48%)
Female (%)	56.0	75.0	44.4	58.3
Onset age (yr, mean $\pm$ SD)	58.6 $\pm$ 11.1	49 $\pm$ 11.3	60.9 $\pm$ 10.8	60.1 $\pm$ 9.4
Disease duration (yr, mean $\pm$ SD)	6.9 $\pm$ 3.9	8.5 $\pm$ 5.3	7.8 $\pm$ 4.7	5.7 $\pm$ 2.9
LED median/mean $\pm$ SD	900/922 $\pm$ 377	775/849 $\pm$ 409	826/964 $\pm$ 423	938/915 $\pm$ 363
LED range	200–1900	450–1397	600–1900	200–1500
Dyskinesia	6 (24%)	3 (75%)	3 (33.3%)	0
Wearing off	9 (36%)	4 (100%)	5 (55.6%)	0
<b>PSP</b>				
Subjects (% total PSP)	18	3 (16.7%)	5 (27.8%)	10 (55.6%)
Female (%)	33.3	66.7	40	40
Onset age (yr, mean $\pm$ SD)	69.3 $\pm$ 7.9	71.3 $\pm$ 6.7	76.9 $\pm$ 7.6	65.0 $\pm$ 5.3
Disease duration (yr, mean $\pm$ SD)	9.1 $\pm$ 5.6	17.0 $\pm$ 4.9	8.2 $\pm$ 6.3	7.2 $\pm$ 3.3
LED median/mean $\pm$ SD	875/924 $\pm$ 373	851/934 $\pm$ 236	750/810 $\pm$ 272	1050/978 $\pm$ 455
LED range	300–1630	750–1200	451–1200	300–1630
Dyskinesia	5 (27.8%)	1 (33.3%)	4 (80%)	0
Wearing off	5 (27.8%)	2 (66.7%)	3 (60%)	0
<b>CBD</b>				
Subjects (% total CBD)	8	–	1 (12.5%)	7 (87.6%)
Female (%)	25.0	–	100	14.3
Onset age (yr, mean $\pm$ SD)	63.9 $\pm$ 9.0	–	66.8	63.5 $\pm$ 9.6
Disease duration (yr, mean $\pm$ SD)	6.9 $\pm$ 4.6	–	6.9	6.9 $\pm$ 4.9
LED median/mean $\pm$ SD	975/943 $\pm$ 336	–	1064	900/926 $\pm$ 359
LED range (median)	450–1500	–	1064	450–1500
Dyskinesia	1 (12.5%)	–	1	0
Wearing off	1 (12.5%)	–	1	0

Abbreviations: PD, Parkinson's disease; SD, standard deviation; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; LED, levodopa equivalent dose (mg).

**TABLE 2.** Other pathological diagnoses and medication response

Diagnosis	Patients	Women	Onset age (yr, mean $\pm$ SD)	Duration (yr, mean $\pm$ SD)	Medication response				Wearing off
					Marked	Moderate	Nil	Dyskinesias	
Vascular disease	7	2	74.2 $\pm$ 4.8	10.7 $\pm$ 5.3	—	3	4	—	2
Alzheimer's disease	2	1	60.5 $\pm$ 3.5	7.7 $\pm$ 2.5	—	—	2	—	—
NBIA	2	—	63.8 $\pm$ 10.2	7.1 $\pm$ 5.6	—	1	1	—	—
PART	2	1	70.5 $\pm$ 0.7	16.8 $\pm$ 6.4	—	1	1	—	1
CJD	1	—	75.1	7.5	—	—	1	—	—
AGD	1	—	72.0	13.6	—	—	1	—	—
Huntington's disease	1	—	24.0	18.1	—	1	—	—	—
Mitochondrial mutation	1	1	51.0	11.7	—	1	—	—	—
HIE	1	—	67.0	18.7	—	—	1	—	—
NPH	1	1	70.0	13.5	—	—	1	—	—
Unexplained	5	3	64.4 $\pm$ 17.1	11.8 $\pm$ 4.4	—	2	3	2	2

Abbreviations: SD, standard deviation; NBIA, neurodegeneration with brain iron accumulation; PART: primary age-related tauopathy; CJD, Creutzfeldt–Jakob disease; AGD, argyrophilic grain disease; HIE, hypoxic–ischemic encephalopathy; NPH, normal pressure hydrocephalus.

co-diagnosis of PD was present in 4, AD in 1, non-vascular amyloid in 10, TDP43 in 1, and PART in 2. One PSP case had a co-diagnosis of NBIA. In CBD, a co-diagnosis of PD was present in 1; nonvascular amyloid was observed in 5.

The mean age of onset (Table 1) differed among the diagnostic groups as determined by the Kruskal–Wallis test ( $H = 11.708$ ,  $df = 3$ ,  $P = 0.008$ ). A post hoc pairwise multiple comparison procedure (Dunn) showed significant differences in the age of onset as follows: MSA < PSP ( $P < 0.05$ ) and PD < PSP ( $P < 0.05$ ). Comparisons of other pairs were nonsignificant. The mean disease duration also differed among groups ( $H = 56.029$ ,  $df = 3$ ,  $P < 0.001$ ). Post hoc pairwise comparisons showed significant differences in disease duration as follows: PD > CBD ( $P < 0.05$ ), PD > MSA ( $P < 0.05$ ), and PD > PSP ( $P < 0.05$ ), with other pairwise comparisons being nonsignificant. There was no significant sex difference among groups ( $\chi^2 = 7.03$ ).

LEDs at peak benefit in individual patients varied widely, ranging from 150 to 2843 mg/day (mean 795 mg/day), in those with PD who exhibited a marked response to dopamine replacement. There was no significant difference in mean LED between responders (marked/moderate) and nonresponders in any of the major patient groups. Few of the nonresponding patients received an LED <600 mg/day (PD, 2 patients; MSA, 1 patient; PSP, 2 patients; and CBD, 1 patient). In the group of participants with other diagnoses, 9 individuals had a moderate response to dopaminergic therapy (mean dose:  $1045 \pm 424$  mg), including 2 in whom the movement disorder remained unexplained after autopsy. LEDs are summarized in Table 1.

The presence of multiple pathologies did not correlate with medication response. In PD, the age of onset correlated significantly with medication response (Kruskal–Wallis;  $H = 15.597$ ,  $df = 2$ ,  $P < 0.001$ ), with marked

response < no response. Disease duration also correlated with medication response (Kruskal–Wallis;  $H = 16.639$ ,  $df = 2$ ,  $P < 0.001$ ), with marked response > no response.

## Discussion

A clear and dramatic beneficial response to dopaminergic therapy is considered to be a supportive criterion for the clinical diagnosis of PD.<sup>1</sup> In our study, approximately 91% of PD participants had a marked or moderate response to dopaminergic medication. Unequivocal wearing off was present in 23 of 41 of our patients with a clinically moderate response, consistent with MDS criteria defining a dramatic response for these patients.<sup>1</sup> Using this definition, at least 81.3% of PD patients have a dramatic response to dopaminergic medication. The absence of an observable response to high-dose levodopa (defined in the MDS criteria as  $\geq 600$  mg/day) despite at least moderate clinical severity of disease is considered to be an absolute exclusion for the diagnosis.<sup>1</sup> After excluding patients receiving <600 mg/day and ensuring appropriate disease severity, approximately 7.7% of our autopsy-proven PD patients would have been misdiagnosed clinically, suggesting that this criterion for absolute exclusion should be used with caution. None of the nonresponders developed dyskinesias or motor fluctuations in response to dopaminergic treatment, supporting our impression that these are true nonresponders.

This study also confirms observations from previous studies that a response to dopaminergic therapy is not specific for PD. We found that, in other neurodegenerative disorders associated with parkinsonism, a marked or moderate dopaminergic response was often present although not as frequently as in PD. In MSA, the

second most common confirmed diagnosis, 52% had a marked or moderate response to dopaminergic medication, whereas in PSP 44% had this degree of response. In CBD, there was only 1 dopaminergic responder although the number of patients in this group was relatively low in comparison to the other groups. A marked response was present in 7 of 51 non-PD patients. The disease duration in all groups was comparable to literature reports.<sup>18</sup> These results are similar to those previously reported by Rajput and colleagues from a 22-year study of 59 patients with parkinsonism, of whom 37 received an adequate trial of levodopa (defined as at least half of the usual dose for at least 2 months).<sup>19</sup> In this study, symptomatic improvement was evident in 94% of patients with pathologically confirmed PD and in 33% of MSA cases.

An important caveat to our observations is that we are not addressing primarily the accuracy of a clinical diagnosis of PD but the spectrum of pathological entities underlying the clinical manifestation of parkinsonism. The range of pathological diagnoses is comparable to that in previous reports that also found MSA to be the second most common pathological diagnosis after PD in patients with parkinsonism.<sup>20</sup> Hughes and colleagues have reported that the accuracy of the clinical diagnosis of PD can be as high as 90%.<sup>21</sup> Others have emphasized the importance of long-term follow-up in establishing an accurate clinical diagnosis.<sup>22,23</sup>

Interestingly, in the 24 patients with other diagnoses, there were still 9 with a moderate response (including 5 with wearing off) to dopaminergic therapy, including 2 in whom the movement disorder remained unexplained after autopsy, providing further evidence of the lack of diagnostic specificity of dopaminergic response.

Average LEDs at the time of peak benefit early in the disease course were comparable in all groups, making it unlikely that the group difference in medication response was related to dose. Although it is possible that some patients would respond to a higher LED than was administered, this is not likely to be a major issue in our patient population because only 2 nonresponders in each of the PD and PSP groups and 1 in each of the MSA and CBD groups received <600 mg LED/day. Our routine practice is to administer dopaminergic medication with an escalating dose until there is adequate symptomatic benefit or dose-limiting side effects. With the exception of 1 patient with PSP and 2 with MSA, all of the nonresponders in this study received treatment for more than 6 months.

Notwithstanding the 600 mg/day recommendation from the MDS Clinical Diagnostic Criteria for Parkinson's Disease noted earlier, an unresolved challenge in clinical practice relates to the dosage of levodopa that must be administered before the patient is considered nonresponsive.<sup>24</sup> Hauser and colleagues

reported that a substantial percentage of patients receiving up to 600 mg/day of levodopa fail to exhibit a robust response in a cohort of previously untreated PD patients enrolled in the ELLDOPA study.<sup>25</sup> At 24 weeks after starting medication, 26.3% of levodopa-treated participants in this study experienced an improvement of 10% or less compared with baseline. These patients, however, had clinically diagnosed PD without autopsy confirmation. In a review of autopsy-confirmed patients, Hughes and colleagues<sup>2</sup> reported initial response to levodopa to be "nil to poor" in 6 of 95 patients receiving a dose of "usually 1000 mg/d," which is consistent with our findings. In contrast, in a study of 1007 patients with clinically diagnosed PD, a limited response to levodopa challenge was evident in 39% of participants.<sup>26</sup> The levodopa dose in those exhibiting a limited response was relatively low at  $485 \pm 215$  mg/day. Mark and colleagues reported 2 cases of autopsy-confirmed PD who were non-responsive to carbidopa/levodopa (75/750 mg/day, 100/1000 mg/day), further emphasizing that PD cannot be excluded by a lack of levodopa response.<sup>27</sup>

Dopamine responsiveness in MSA similar to the 52% that we observed has been reported previously. Wenning and colleagues reported a beneficial response in 42% of autopsy-proven MSA patients versus 77% of those with PD.<sup>28</sup> These authors acknowledge that clinicians may sometimes not increase levodopa doses sufficiently to gain a response but do not state what doses their patients were receiving. A similar degree of response was reported by the North American MSA Study Group, but dose issues were not provided.<sup>29</sup> Hughes and colleagues reported an initial response to levodopa of >50% in approximately 43% of autopsy-proven MSA patients who had received a mean dose of 580 mg/day.<sup>30</sup> The consensus statement regarding MSA diagnosis recommends escalating the doses of levodopa to at least 1 g/day (if necessary and tolerated).<sup>31</sup>

Although a poor or absent response to levodopa (LD) has previously been one of the clinical diagnostic criteria for PSP, several papers have reported a beneficial response similar to the 44% that we observed. This can potentially lead to an incorrect diagnosis of PD in patients with PSP, particularly in view of our previous observation that supranuclear gaze palsy is not uncommon in people with PD.<sup>32</sup> Lang suggests that the overall response rate to LD in PSP is about 26%.<sup>33</sup> A retrospective review of 87 clinically diagnosed PSP patients reported a benefit from LD in 38% of patients.<sup>34</sup> A clinicopathological study involving 103 cases of PSP reported that a trial of LD or dopamine agonist was undertaken in 88%.<sup>35</sup> No patient had an "excellent" response, but 32% had a modest or good response although the dosage was not reported. In this study, individuals with the parkinsonism-PSP subtype were more likely to show a benefit than those with the

Richardson syndrome subtype (50% vs. 14.3%). The current diagnostic criteria for PSP include levodopa resistance while receiving at least 1000 mg of levodopa for at least 1 month.<sup>36</sup> Our study suggests that this approach would misclassify about a third of people with PSP.

CBD as a cause of parkinsonism is observed less frequently than the other disorders described. Only 8 of our participants (3.1%) had autopsy-confirmed CBD, 1 of whom had a moderate response to dopaminergic medications. Kompoliti and colleagues suggest a higher rate of response in a review of 147 individuals clinically diagnosed (confirmed by autopsy in only 7) with CBD from 8 centers.<sup>3</sup> Symptomatic improvement was observed in 24% of cases who were receiving dopaminergic medications. The median levodopa dose in these patients was 300 mg/day.

Dementia with Lewy bodies (DLB) is not represented in our patient population in large part because DLB does not have a disease-specific pathological marker. Substantial pathological overlap exists between DLB and PD with dementia. Most of our PD patients had not only brainstem changes but also cortical  $\alpha$ -synucleinopathy, the characteristic pathology of both PD with dementia and DLB. Pathologically, these 2 conditions are indistinguishable. In fact, both conditions represent the same synucleinopathy, with clinicopathologic diagnosis assigned according to the timing of onset of the dementia with respect to onset of motor parkinsonism. In addition, our brain bank reflects the bias of those patients referred to a movement disorder center. By definition, patients with DLB have cognitive changes that precede or occur within 1 year of the onset of the movement disorder; these individuals are more likely to seek evaluation at a dementia center.

Neuropathological changes consistent with AD were present in 6 of 182 PD patients. Nonvascular amyloid deposition not meeting the criteria for AD was present in another 127 patients. This is comparable to previous observations of A $\beta$  deposition with at least moderate neocortical tauopathy (compatible with the presence of neurofibrillary tangles and/or neuritic plaques) in only 1 of 32 autopsied patients with PD and dementia, corresponding to a high likelihood of AD based on NIA-Reagan diagnostic criteria.<sup>37</sup> In contrast, this study found A $\beta$  deposition with minimal or no cortical tau in 19 of 32 patients, suggesting that A $\beta$  deposition alone does not necessarily indicate AD in the context of PD. Irwin and colleagues reported the autopsy studies of 140 patients with a clinical diagnosis of PD, 48 of whom were cognitively normal, versus 92 with dementia.<sup>38</sup> A total of 28.6% of all PD cases had sufficient pathology for comorbid AD, of whom 89.5% were demented. However, these investigators used a less-stringent criterion for a neuropathological diagnosis of

AD, namely an intermediate or high probability of AD versus the high likelihood used in our study. Because our aim was to evaluate the dopaminergic motor response and its association with pathologically confirmed diagnoses, we did not assess cognition in the present study and cannot address dementia prevalence in our patients.

Why do some patients who are ultimately shown pathologically to have PD show no response to levodopa? Age may be an important factor. In our study, the nonresponders had a significantly greater age of onset than did those with a marked response. Nonresponders also had a shorter disease duration. LED did not differ between these groups. Although it is possible that at least some of the nonresponders may have responded to a higher dose, these patients were not treated differently in the clinic where all patients with parkinsonism receive an escalating medication dose based on individual patient tolerance.

Our study does have some limitations. As a retrospective chart review, it is dependent on the accuracy of clinical information available within the medical record. Not all patients had clinical findings recorded in the form of a UPDRS motor rating and, for practical reasons, assessments were not always done in both the ON and OFF states. However, subspecialty-trained movement disorders neurologists were responsible for all assessments, and the narrative record provided a good indication of the degree of response to dopaminergic medications. The history of medication use and medication dose was available for all patients. Selection bias is unlikely to be a major issue. All patients in our center are routinely invited to participate in our brain donation program early in the course of their clinic involvement, regardless of clinical diagnosis. Furthermore, the distribution of pathological diagnoses in this study is comparable to the distribution of clinical diagnoses in our center. Although we acknowledge that there are other important measures relating to the clinical diagnosis of PD and listed in the MDS clinical diagnostic criteria,<sup>1</sup> our intent was to assess the dopaminergic response specifically and not to evaluate the overall accuracy of the criteria. Similarly, we have not addressed the accuracy of the clinical diagnosis itself in our patients or the evolving nature of clinical diagnoses as disease progresses.

These observations provide useful information regarding the sensitivity and specificity of the response to dopamine replacement medications as a disease marker. Our data indicate that a substantial response is frequent but not universal in PD. An absent response does not exclude PD. In other neurodegenerative disorders associated with parkinsonism, a significant response may also be evident although less frequently than in PD. Our data in addition to previously

published data on medication response suggest that using the absence of an observable response to a levodopa dose  $\geq 600$  mg/day as an exclusion for the diagnosis of PD as recommended in the MDS Clinical Diagnostic Criteria for Parkinson's Disease<sup>1</sup> merits reconsideration. ■

**Acknowledgments:** This work was supported by grants from the National Institutes of Health (NS07532, NS097799, U10NS077384), the American Parkinson Disease Association (APDA), the Greater St. Louis Chapter of the APDA, the Jo Oertli Fund, the Barnes Jewish Hospital Foundation (Elliot Stein Family Fund and the Parkinson Disease Research Fund), and the Paula and Rodger Riney Fund. We thank our patients and families without whom this research would not be possible.

## References

- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015;30:1591–1601.
- Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. *Arch Neurol* 1993;50:140–148.
- Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. *Arch Neurol* 1998;55:957–961.
- O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. *Brain* 2008;131:1362–1372.
- Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. *Lancet Neurol* 2004;3:93–103.
- Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. *Arch Neurol* 2010;67:64–70.
- Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disorder* 2010;25:2649–2685.
- Franklin EE, Perrin RJ, Vincent B, Baxter M, Morris JC, Cairns NJ. Alzheimer's disease neuroimaging initiative. brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's disease neuroimaging initiative participants. *Alzheimers Dement* 2015;11:815–822.
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003;24:197–211.
- McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. *Neurology* 1996;47:1113–1124.
- Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. *J Neurol Sci* 1999;163:94–98.
- Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett* 1998;251:205–208.
- Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. *J Neuropathol Exp Neurol* 1996;55:97–105.
- Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. *J Neuropathol Exp Neurol* 2002;61:935–946.
- Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. *Neurobiol Aging* 1997;18 (suppl 4):S1–S2.
- Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. *Acta Neuropathol* 2007;114:5–22.
- Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol* 2014;128:755–766.
- Erkkinen MG, Kim M-O, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. *Cold Spring Harb Perspect Biol* 2018;10:a033118.
- Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. *Clin Neuropharm* 1990;13:553–558.
- Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism – a prospective study. *Can J Neurol Sci* 1991;18:275–278.
- Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. *Neurology* 2001;57:1497–1499.
- Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease. *Clinicopathologic study*. *Neurology* 2014;83:406–412.
- Adler CH, Beach TG. Importance of low diagnostic accuracy for early Parkinson's disease. *Mov Disord* 2018;33:1551–1554.
- Nonnikes J, Timmer MHM, DeVries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson's disease. *Mov Disord* 2018;31:1602–1608.
- Hauser RA, Auner PD, Oakes D, Parkinson Study Group. Levodopa response in early Parkinson's disease. *Mov Disord* 2009;24:2328–2336.
- Malek N, Kanavou S, Lawton MA, et al. L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. *Parkinsonism Relat Disord* 2019;65:55–61.
- Mark MH, Sage JI, Dickson DW, Schwarz KO, Duvoisin RC. Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases. *Neurology* 1992;42:1323–1327.
- Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? *J Neurol Neurosurg Psychiatry* 2000;68:434–440.
- Gilman S, May SJ, Shults CW, et al. The North American multiple system atrophy study group. *J Neural Transm (Vienna)* 2005;112:1687–1694.
- Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1992;55:1009–1013.
- Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 2008;71:670–676.
- Martin WRW, Hartlein J, Racette BA, Cairns N, Perlmuter JS. Pathologic correlates of supranuclear gaze palsy with parkinsonism. *Parkinsonism Relat Disord* 2017;38:68–71.
- Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. *Mov Disord* 2005;20:S83–S91.
- Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. *Clin Neuropharmacol* 1993;16:338–346.
- Williams DR, de Silva R, Pavlou DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. *Brain* 2005;128:1247–1258.
- Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. *Mov Disord* 2017;32:853–864.
- Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of  $\alpha$ -synuclein and  $\beta$ -in Parkinson disease patients with dementia. *Arch Neurol* 2012;69:1326–1331.
- Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol* 2012;72:587–598.